Determining Optimum Hemoglobin Sampling for Anemia Management from Every-Treatment Data

被引:20
|
作者
Gaweda, Adam E. [1 ]
Nathanson, Brian H. [2 ]
Jacobs, Alfred A.
Aronoff, George R.
Germain, Michael J. [3 ]
Brier, Michael E. [4 ]
机构
[1] Univ Louisville, Dept Med, Div Nephrol, Louisville, KY 40202 USA
[2] OptiStatim LLC, Longmeadow, MA USA
[3] Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA
[4] Robley Rex Med Ctr, Dept Vet Affairs, Louisville, KY USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2010年 / 5卷 / 11期
基金
美国国家卫生研究院;
关键词
LEVEL VARIABILITY; HEMODIALYSIS; ASSOCIATIONS; MORTALITY; DISEASE;
D O I
10.2215/CJN.03540410
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Anemia Management Protocols in ESRD call for hemoglobin (Hb) monitoring every 2 to 4 weeks. Short-term Hb variability affects the reliability of Hb measurement and may lead to incorrect dosing of erythropoiesis stimulating agents. We prospectively analyzed short-term Hb variability and quantified the relationship between frequency of Hb monitoring and error in Hb estimation. Design, setting, participants, & measurements: Using the Crit-Line III TQA device, we prospectively observed Hb during each dialysis treatment in 49 ESRD patients and quantified long- and short-term Hb variability. We estimated Hb from data sampled at regular intervals; 8x, 4x, 2x, or 1x per month to establish how well we account for short-term variability at different monitoring intervals. We calculated the Hb estimation error (Hb(err)) as a root mean-squared difference between the observed and estimated Hb and compared it with the measurement error. Results: The most accurate Hb estimation is achieved when monitoring 8x per month (Hb(err) = 0.23 +/- 0.05 g/dl), but it exceeds the accuracy of the measurement device. The estimation error increases to 0.34 +/- 0.07 g/dl when monitoring 4x per month, 0.39 +/- 0.08 g/dl when monitoring 2x a month, and 0.45 +/- 0.09 g/dl when monitoring 1x per month. Estimation error comparable to instrument error information is as follows: 8x per month, 15 patients; 4x per month, 22 patients; 2x per month, 6 patients; 1x per a month, 6 patients. Conclusions: Four times a month is the clinically optimal Hb monitoring frequency for anemia management. Clin J Am Soc Nephrol 5: 1939-1945, 2010. doi: 10.2215/CJN.03540410
引用
收藏
页码:1939 / 1945
页数:7
相关论文
共 50 条
  • [21] An ensemble machine learning approach for determination of the optimum sampling time for evapotranspiration assessment from high-throughput phenotyping data
    Kar, Soumyashree
    Purbey, Vikram Kumar
    Suradhaniwar, Saurabh
    Korbu, Lijalem Balcha
    Kholova, Jana
    Durbha, Surya S.
    Adinarayana, J.
    Vadez, Vincent
    COMPUTERS AND ELECTRONICS IN AGRICULTURE, 2021, 182
  • [22] Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR)
    Hertel, J
    Locay, H
    Scarlata, D
    Jackson, L
    Prathikanti, R
    Audhya, P
    AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (02) : 149 - 156
  • [23] Commentary on ICH guideline on genomic sampling and data management-enabling opportunities in drug development and patient treatment
    Ehmann, Falk
    Aerssens, Jeroen
    Blanchard, Rebecca
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (08) : 1454 - 1464
  • [24] Analysis of the relationship between lifestyle habits and glycosylated hemoglobin control based on data from a Health Management Plan
    Wang, Ya-Chun
    Wang, Chi
    Shih, Ping-Wen
    Tang, Pei-Ling
    NUTRITION RESEARCH AND PRACTICE, 2020, 14 (03) : 218 - 229
  • [26] Data From the Diamond Blackfan Anemia Registry (Dbar) Suggest A Reevaluation Of Current Treatment Practices † 804
    A Vlachos
    R Boonyasai
    J Abramson
    J Samedi
    C Reyes-Haley
    B P Alter
    G R Buchanan
    M H Freedman
    B E Glader
    J M Lipton
    Pediatric Research, 1998, 43 (Suppl 4) : 139 - 139
  • [27] Darbepoetin alfa as a treatment for chemotherapy-induced anemia: An integrated analysis of data from multiple studies
    Hedenus, M
    Vansteenkiste, J
    Poulsen, E
    Rossi, G
    Glapsy, J
    BLOOD, 2002, 100 (11) : 17B - 18B
  • [28] Bone Marrow Sampling in Aplastic Anemia and Neuroblastoma in Children and Adolescents: A Retrospective Data from a Single Tertiary Care Centre in Eastern India
    Padhi, Somanath
    Panigrahi, Chinmayee
    Mishra, Swetasmita
    Mohapatra, Sonali
    Ayaanar, Pavithra
    Sahoo, Debashis
    Parida, Tapaskanti
    Mohapatra, Rakesh Kumar
    Sahoo, Durgesh Prasad
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024,
  • [29] Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
    Raptis, Anastasios
    Duh, Mei Sheng
    Wang, Si-Tien
    Dial, Ellison
    Fanourgiakis, Ilias
    Fortner, Barry
    Paley, Carole
    Mody-Patel, Nikita
    Corral, Mitra
    Scott, Jeffrey
    TRANSFUSION, 2010, 50 (01) : 190 - 199
  • [30] ON THE RECOVERY AND RESOLUTION OF EXPONENTIAL RELAXATION RATES FROM EXPERIMENTAL-DATA .2. THE OPTIMUM CHOICE OF EXPERIMENTAL SAMPLING POINTS FOR LAPLACE TRANSFORM INVERSION
    BERTERO, M
    BOCCACCI, P
    PIKE, ER
    PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON SERIES A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES, 1984, 393 (1804): : 51 - 65